Drugs / GLPG CAR T-cell therapy
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06652633 | Sep 2024 → Jul 2039 expected | hematopoietic and lymphoid cell neoplasm | Lakefront Biotherapeutics NV | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GLPG CAR T-cell therapy | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06652633 ↗ |
| Modality | Cell therapy | “Galapagos (GLPG) CAR T-cell therapies” NCT06652633 ↗ |